Zosano Pharma Posts Trial Titled ‘Crossover Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers’ To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04969497
Zosano Pharma Announces Issuance Of U.S. Patent For Method Of Rapidly Achieving Therapeutic Levels With M207 For The Acute Treatment Of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No.
22 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
SCWorx (NASDAQ:WORX) shares rose 8.38% to $1.81 during Monday's after-market session. SCWorx's trading volume hit 504.7K shares by close, accounting for 148.37% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.1 million.
60 Biggest Movers From Yesterday
Gainers
Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related logistics assets.
Why Zosano Pharma’s Stock Is Trading Higher Today
Zosano Pharma (NASDAQ:ZSAN) shares are trading higher after the company announced publication of clinical data regarding the long-term use of Qtrypta for the treatment of acute migraine in The Journal of Headache and Pain.